Join
Live feed
·
PRReleasevia Quantisnow
Monopar Therapeutics Inc. logo

Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

ByQuantisnow·Wall Street's wire, on your screen.
MNPR· Monopar Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNPR (Monopar Therapeutics Inc.) and more on Quantisnow.